New studies on cost savings through medicine imports in EU countries

The European Association of Euro-Pharmacuetical Companies, EAEPC, changed its name to 'Affordable Medicines Europe'.

The new name better reflects the industrys right to exist, namely to make medicines for healthcare systems and patients in the EU more affordable. Imports of inexpensive original medicines are often the only competition for the high-priced products of the pharmaceutical manufacturers - especially for patented medicines.

In addition, medicine imports alleviate delivery bottlenecks. New studies show significant direct and indirect cost savings through parallel imports for EU health systems.

Details can be found in the press release at the webpage of the association and the study 'Savings from Parallel Imports in Europe' (annex).

Go back